Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review

References

• Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc. 2014;7:137–146. doi:10.2147/JMDH.S54324
   PubMedGoogle Scholar
• Choi CK, Kim N, Choi JW, et al. Effect of low-dose, enteric coated aspirin on gastrointestinal bleeding in patients with coronary artery disease. Gut Liver. 2008;2(2):99–104. doi:10.5009/gnl.2008.2.2.99
   PubMed Web of Science ®Google Scholar
• Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what’s the risk? Aliment Pharmacol Ther. 2006;24(6):897–908. doi:10.1111/j.1365-2036.2006.03077.x
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Lanas A, Soriano-Gabarró M, Cea Soriano L. Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed severity: a cohort study with nested case-control analysis using primary care electronic health records from the United Kingdom. Ann Med. 2019;51(2):182–192. doi:10.1080/07853890.2019.1591635
   PubMed Web of Science ®Google Scholar
• Chen X, Gao F, Zhang J. Screening for gastric and small intestinal mucosal injury with magnetically controlled capsule endoscopy in asymptomatic patients taking enteric-coated aspirin. Gastroenterol Res Pract. 2018;2018:1–6. doi:10.1155/2018/2524698
   Web of Science ®Google Scholar
• Huang ES, Strate LL, Ho WW, Lee SS, Chan AT, Prospective A. Study of aspirin use and the risk of gastrointestinal bleeding in men. PLoS One. 2010;5(12):e15721.
   PubMed Web of Science ®Google Scholar
• Banoob DW, Banoob DW, McCloskey WW, Webster W. Risk of gastric injury with enteric-versus nonenteric-coated aspirin. Ann Pharmacother. 2002;36(1):163–166. doi:10.1345/aph.18325
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Howden CW, Scheiman J, Tursi J. Upper gastrointestinal toxicity associated with long-term aspirin therapy: consequences and prevention. Curr Probl Cardiol. 2017;42(5):146–164. doi:10.1016/j.cpcardiol.2017.01.006
   PubMed Web of Science ®Google Scholar
• Hirata Y, Kataoka H, Shimura T, et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011;46(7–8):803–809. doi:10.3109/00365521.2011.568522
   PubMed Web of Science ®Google Scholar
• Gao F, Chen X, Zhang J. Prevalence of gastric and small-intestinal mucosal injury in elderly patients taking enteric-coated aspirin by magnetically controlled capsule endoscopy. Gastroenterol Res Pract. 2019;2019:1–5. doi:10.1155/2019/9190367
   Web of Science ®Google Scholar
• Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163–173. doi:10.1185/030079907X162656
   PubMed Web of Science ®Google Scholar
• Newton JL. Improving the gastrointestinal tolerability of aspirin in older people. Clin Interv Aging. 2006;1(1):33–39. doi:10.2147/ciia.2006.1.1.33
   PubMed Web of Science ®Google Scholar
• Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med. 2011;124(5):426–433. doi:10.1016/j.amjmed.2010.12.022
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Scheiman JM, Fort JG, Whellan DJ. Aspirin use in secondary cardiovascular protection and the development of aspirin-associated erosions and ulcers. J Cardiovasc Pharmacol. 2016;68(2):121–126. doi:10.1097/FJC.0000000000000387
   PubMed Web of Science ®Google Scholar
• Walker J, Robinson J, Stewart J, Jacob S. Best evidence topic - coronary does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact Cardiovasc Thorac Surg. 2007;6:519–522.
   PubMedGoogle Scholar
• Chowdhury A, Ganguly G, Chowdhury D, Santra A, Gupta JD, Roy T. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study. Indian J Gastroenterol. 2001;20(6):227–229.
   PubMedGoogle Scholar
• Törüner M. Aspirin and gastrointestinal toxicity. Anadolu Kardiyol Derg. 2007;7(SUPPL. 2):27–30.
   PubMedGoogle Scholar
• de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1–8. doi:10.1186/1472-6904-1-1
   PubMedGoogle Scholar
• Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004;127(2):395–402. doi:10.1053/j.gastro.2004.05.001
   PubMed Web of Science ®Google Scholar
• Shiotani A, Haruma K, Nishi R, et al. Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol. 2010;45(3):292–298. doi:10.3109/00365520903453182
   PubMed Web of Science ®Google Scholar
• Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a Pilot Study. Clin Gastroenterol Hepatol. 2008;6(11):1279–1282. doi:10.1016/j.cgh.2008.06.021
   PubMed Web of Science ®Google Scholar
• Whellan DJ, Goldstein JL, Cryer BL, et al. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, Phase 3 studies. Am Heart J. 2014;168(4):495–502.e4. doi:10.1016/j.ahj.2014.05.017
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–1046. doi:10.1016/S0140-6736(18)31924-X
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Whellan DJ, Scheiman JM, et al. Long-term safety of a coordinated delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg for secondary cardiovascular disease prevention in patients at GI risk. Cardiovasc Ther. 2016;34(2):59–66. doi:10.1111/1755-5922.12172
   PubMed Web of Science ®Google Scholar
• 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease - American College of Cardiology [Internet]; [ cited May 6, 2020]. Available from: https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2019/03/07/16/00/2019-acc-aha-guideline-on-primary-prevention-gl-prevention. Accessed August 10, 2021.
   Google Scholar